{
    "leverage": true,
    "derivatives": true,
    "swaps": true,
    "inverse": true,
    "replication_method": "synthetic",
    "ucits": false,
    "type": "ETP",
    "complex_factors": [
        "Leverage (3x inverse)",
        "Synthetic replication via swaps",
        "Daily reset compounding effect",
        "High risk profile (7/7)",
        "Counterparty risk to Natixis"
    ],
    "classification": "complex",
    "supporting_data": "The GraniteShares 3x Short AstraZeneca Daily ETP is clearly complex under MiFID II due to multiple factors: 1) It uses 3x inverse leverage, which creates a non-linear return profile and significant volatility risk; 2) It employs synthetic replication via swaps with Natixis, introducing counterparty risk; 3) The daily reset mechanism creates compounding effects that make long-term returns unpredictable; 4) The product is classified as risk level 7/7; 5) The KIID explicitly states it is 'not simple and may be difficult to understand'. The PRIIPs KID would likely contain a comprehension alert, further confirming complexity. The fact that it's structured as an ETP (not a UCITS-compliant ETF) and has a 2070 maturity date with unilateral termination rights adds to the complexity. While the collateralization of the swap mitigates some counterparty risk, the overall structure remains too complex for retail investors without specialized knowledge.",
    "confidence": 95
}